Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | TPH1 | P17752 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537569 | 1.00 | SLC7A5 (0.58) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL537570 | 1.00 | SLC7A5 (0.58) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL10927828 | 0.85 | ALOX5 (0.50) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL7608944 | 0.82 | SLC7A5 (0.56) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL7608948 | 0.82 | SLC7A5 (0.56) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL6779373 | 0.78 | SLC1A3 (0.44) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL2310526 | 0.78 | SLC7A5 (0.83) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL2671472 | 0.76 | CYP1A2 (0.46) | PTGS1SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL9812650 | 0.76 | — | — | |
| SCHEMBL23159186 | 0.74 | SLC7A5 (1.00) | SLC7A5PTGS1PKMALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434764-B2 | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2016-09-06 | — | — | US | claimed |
| US-20150299251-A1 | Skin Care Compositions and Methods Comprising Selective Agonists of Melanocortin 1 Receptor | UNIVERSITY OF CINCINNATI (US) | 2015-10-22 | — | — | US | claimed |
| US-20150297667-A1 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | claimed |
| EP-2925340-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-10-07 | — | — | EP | claimed |
| EP-2922565-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014081846-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2014081845-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| EP-2922565-B1 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIV CINCINNATI (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10301355-B2 | Method of using pharmaceutical compositions comprising selective peptide-based agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2925340-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR AND THEIR USE IN THERAPEUTIC METHODS | UNIV CINCINNATI (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180066016-A1 | Pharmaceutical Compositions and Therapeutic Methods of Use Comprising Selective Agonists of Melanocortin 1 Receptor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-08 | — | — | US | disclosed |
| US-9834580-B2 | Pharmaceutical compositions comprising selective peptide-based agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2017-12-05 | — | — | US | disclosed |
| US-9434764-B2 | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2016-09-06 | — | — | US | disclosed |
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2010185-B1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| EP-2010185-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | SLC7A5 3963/4885PTGS1 72/4885PKM 741/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | SLC7A5 2162/4885PTGS1 72/4885PKM 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.